MedTrace Logo

A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

NCT06642792 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2025-02-11

No results posted yet for this study

Summary

This is a phase I/II study. All subjects are patients diagnosed with relapse or refractory (R/R) classic Hodgkin lymphoma (cHL) and has progressed on treatment with PD-1/L1 inhibitor therapy. The purpose of this study is to evaluate the safety and efficacy of AK129 (bispecific antibody targeting LAG-3 and PD-1) monotherapy or in combination with AK117 (anti-CD47 monoclonal antibody) in R/R cHL with PD-1/L1 inhibitor treatment failure.

Conditions

  • Classic Hodgkin Lymphoma

Interventions

DRUG

AK129

Subjects receive AK129 intravenously.

DRUG

AK117

Subjects receive AK117 intravenously.

Sponsors & Collaborators

Principal Investigators

  • Wenting Li, MD · Akeso

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-17
Primary Completion
2027-11-30
Completion
2028-02-29

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06642792 on ClinicalTrials.gov